This study was run to determine if a racial disparity exists in biomarker testing for NSCLC (non-small cell lung cancer) patients.
Jared Safran, PharmD, MS, Russell Robbins, MD, MBA, Maggie Mendes, Douglas Londono, PhD, Grace Kane, MS.
Healthcare is evolving into precision medicine or what the FDA refers to as personalized medicine1. This targeted approach is critical for organizations like pharmaceutical, life science, health plans, and providers to have the tools needed to make safer decisions for their patient populations.
Precision medicine can assist clinicians, help them make more informed decisions regarding available treatment options, and improve patient outcomes.
According to the American Lung Association, people of color with lung cancer face worse outcomes compared to their white American counterparts2.
